$275 Million is the total value of Tri Locum Partners LP's 65 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JNJ | New | JOHNSON & JOHNSON | $25,595,000 | – | 162,633 | +100.0% | 9.30% | – |
| BAX | New | BAXTER INTL INC | $23,969,000 | – | 298,721 | +100.0% | 8.70% | – |
| MDT | New | MEDTRONIC PLC | $23,913,000 | – | 204,138 | +100.0% | 8.68% | – |
| ABBV | New | ABBVIE INC | $20,704,000 | – | 193,223 | +100.0% | 7.52% | – |
| VTRS | New | VIATRIS INC | $19,617,000 | – | 1,046,794 | +100.0% | 7.12% | – |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $17,600,000 | – | 441,324 | +100.0% | 6.39% | – |
| LH | New | LABORATORY CORP AMER HLDGS | $11,013,000 | – | 54,105 | +100.0% | 4.00% | – |
| CCXI | New | CHEMOCENTRYX INC | $10,283,000 | – | 166,077 | +100.0% | 3.73% | – |
| LLY | New | LILLY ELI & CO | $9,374,000 | – | 55,521 | +100.0% | 3.40% | – |
| ZLAB | New | ZAI LAB LTDadr | $8,423,000 | – | 62,235 | +100.0% | 3.06% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $8,289,000 | – | 73,906 | +100.0% | 3.01% | – |
| ANTM | New | ANTHEM INC | $7,505,000 | – | 23,374 | +100.0% | 2.73% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $7,237,000 | – | 271,974 | +100.0% | 2.63% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $6,945,000 | – | 121,409 | +100.0% | 2.52% | – |
| INCY | New | INCYTE CORP | $5,861,000 | – | 67,384 | +100.0% | 2.13% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $5,227,000 | – | 259,283 | +100.0% | 1.90% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $5,035,000 | – | 10,423 | +100.0% | 1.83% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $4,635,000 | – | 40,159 | +100.0% | 1.68% | – |
| New | TRILLIUM THERAPEUTICS INC | $4,366,000 | – | 296,838 | +100.0% | 1.59% | – | |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $4,297,000 | – | 56,003 | +100.0% | 1.56% | – |
| TGTX | New | TG THERAPEUTICS INC | $3,638,000 | – | 69,932 | +100.0% | 1.32% | – |
| ALXO | New | ALX ONCOLOGY HLDGS INC | $3,381,000 | – | 39,226 | +100.0% | 1.23% | – |
| AXNX | New | AXONICS MODULATION TECHNOLOG | $3,214,000 | – | 64,378 | +100.0% | 1.17% | – |
| LSAQ | New | LIFESCI ACQUISITION II CORP | $3,201,000 | – | 300,000 | +100.0% | 1.16% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $3,068,000 | – | 56,402 | +100.0% | 1.11% | – |
| CRIS | New | CURIS INC | $2,954,000 | – | 360,697 | +100.0% | 1.07% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $2,832,000 | – | 157,403 | +100.0% | 1.03% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,643,000 | – | 118,833 | +100.0% | 0.96% | – |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $2,609,000 | – | 728,710 | +100.0% | 0.95% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,700,000 | – | 19,832 | +100.0% | 0.62% | – |
| ONCT | New | ONCTERNAL THERAPEUTICS INC | $1,400,000 | – | 285,714 | +100.0% | 0.51% | – |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $1,369,000 | – | 658,373 | +100.0% | 0.50% | – |
| NMTR | New | 9 METERS BIOPHARMA INC | $1,195,000 | – | 1,390,821 | +100.0% | 0.43% | – |
| ARCT | New | ARCTURUS THERAPEUTICS HLDGS | $1,159,000 | – | 26,722 | +100.0% | 0.42% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $1,130,000 | – | 40,910 | +100.0% | 0.41% | – |
| TARA | New | PROTARA THERAPEUTICS INC | $950,000 | – | 39,225 | +100.0% | 0.34% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $877,000 | – | 49,373 | +100.0% | 0.32% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $688,000 | – | 7,178 | +100.0% | 0.25% | – |
| PG | New | PROCTER AND GAMBLE CO | $447,000 | – | 3,210 | +100.0% | 0.16% | – |
| BTAI | New | BIOXCEL THERAPEUTICS INC | $445,000 | – | 9,630 | +100.0% | 0.16% | – |
| MDLZ | New | MONDELEZ INTL INCcl a | $386,000 | – | 6,608 | +100.0% | 0.14% | – |
| CL | New | COLGATE PALMOLIVE CO | $371,000 | – | 4,343 | +100.0% | 0.14% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $356,000 | – | 62,000 | +100.0% | 0.13% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $330,000 | – | 10,283 | +100.0% | 0.12% | – |
| VZ | New | VERIZON COMMUNICATIONS INC | $319,000 | – | 5,437 | +100.0% | 0.12% | – |
| COST | New | COSTCO WHSL CORP NEW | $317,000 | – | 841 | +100.0% | 0.12% | – |
| KMB | New | KIMBERLY-CLARK CORP | $309,000 | – | 2,291 | +100.0% | 0.11% | – |
| PEN | New | PENUMBRA INC | $297,000 | – | 1,695 | +100.0% | 0.11% | – |
| MRK | New | MERCK & CO. INC | $297,000 | – | 3,631 | +100.0% | 0.11% | – |
| HRL | New | HORMEL FOODS CORP | $287,000 | – | 6,148 | +100.0% | 0.10% | – |
| HSY | New | HERSHEY CO | $281,000 | – | 1,842 | +100.0% | 0.10% | – |
| GIS | New | GENERAL MLS INC | $282,000 | – | 4,799 | +100.0% | 0.10% | – |
| CHD | New | CHURCH & DWIGHT INC | $278,000 | – | 3,185 | +100.0% | 0.10% | – |
| K | New | KELLOGG CO | $275,000 | – | 4,416 | +100.0% | 0.10% | – |
| MKC | New | MCCORMICK & CO INC | $274,000 | – | 2,863 | +100.0% | 0.10% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $260,000 | – | 4,197 | +100.0% | 0.09% | – |
| BCE | New | BCE INC | $249,000 | – | 5,825 | +100.0% | 0.09% | – |
| CLX | New | CLOROX CO DEL | $249,000 | – | 1,234 | +100.0% | 0.09% | – |
| TU | New | TELUS CORPORATION | $234,000 | – | 11,793 | +100.0% | 0.08% | – |
| FLO | New | FLOWERS FOODS INC | $230,000 | – | 10,182 | +100.0% | 0.08% | – |
| UL | New | UNILEVER PLCspon adr new | $225,000 | – | 3,725 | +100.0% | 0.08% | – |
| CPB | New | CAMPBELL SOUP CO | $214,000 | – | 4,432 | +100.0% | 0.08% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $129,000 | – | 17,260 | +100.0% | 0.05% | – |
| KDMN | New | KADMON HLDGS INC | $65,000 | – | 15,618 | +100.0% | 0.02% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $51,000 | – | 14,557 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 10 | Q3 2023 | 0.5% |
| REGENERON PHARMACEUTICALS | 9 | Q3 2023 | 13.8% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| XENON PHARMACEUTICALS INC | 8 | Q3 2023 | 2.4% |
| ARGENX SE | 7 | Q3 2023 | 12.8% |
| STEVANATO GROUP S P A | 7 | Q2 2023 | 5.8% |
| PROTAGONIST THERAPEUTICS INC | 7 | Q2 2023 | 7.1% |
| AVADEL PHARMACEUTICALS PLC | 7 | Q3 2023 | 6.4% |
| BELLUS HEALTH INC NEW | 7 | Q3 2022 | 4.3% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.